Provided by Tiger Fintech (Singapore) Pte. Ltd.

Immunovant, Inc.

16.42
+1.228.03%
Post-market: 15.93-0.4900-2.98%18:33 EDT
Volume:3.71M
Turnover:59.50M
Market Cap:2.79B
PE:-6.28
High:16.58
Open:15.02
Low:14.90
Close:15.20
Loading ...

Immunovant, Inc. (IMVT): Among Stocks Insiders Spent The Most Money On Recently

Insider Monkey
·
20 Feb

Analysts Offer Insights on Healthcare Companies: Pacific Biosciences (PACB), Immunovant (IMVT) and 4D Molecular Therapeutics (FDMT)

TIPRANKS
·
11 Feb

Q3 2024 Roivant Sciences Ltd Earnings Call

Thomson Reuters StreetEvents
·
11 Feb

Stock Track | Immunovant, Inc. Plummets 5.10% on Wider-Than-Expected Quarterly Loss

Stock Track
·
11 Feb

Immunovant Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
10 Feb

Immunovant Is Maintained at Buy by Guggenheim

Dow Jones
·
10 Feb

J.P. Morgan Keeps Their Buy Rating on Immunovant (IMVT)

TIPRANKS
·
08 Feb

Immunovant Price Target Maintained With a $51.00/Share by HC Wainwright & Co.

Dow Jones
·
08 Feb

Immunovant’s Strategic Positioning and Financial Strength Propel IMVT-1402 Towards Pivotal Studies

TIPRANKS
·
08 Feb

IMVT Q3 Loss Wider Than Expected, Stock Down, Pipeline in Focus

Zacks
·
07 Feb

Immunovant's Fiscal Q3 Loss Widens

MT Newswires Live
·
06 Feb

Immunovant Q3 2025 GAAP EPS $(0.76), Inline, Pro Forma Cash Balance Of Approximately $825M As Of December 31, 2024, Including Approximately $450M Gross Proceeds From A Private Placement

Benzinga
·
06 Feb

Immunovant Inc: as of December 31, 2024, Co's Cash and Cash Equivalents Totaled $374.7 Million

THOMSON REUTERS
·
06 Feb

BRIEF-Immunovant Q3 Net Income USD -111.122 Million

Reuters
·
06 Feb

Immunovant Q3 Basic EPS USD -0.76

THOMSON REUTERS
·
06 Feb

Immunovant Q3 Net Income USD -111.122 Million

THOMSON REUTERS
·
06 Feb

Press Release: Immunovant Reports Financial Results for the Quarter Ended December 31, 2024

Dow Jones
·
06 Feb

BRIEF-Immunovant Inc Selling Stockholders To Offer Up To 5.7 Million Shares Of Common Stock- SEC Filing

Reuters
·
25 Jan

Immunovant, Inc. (IMVT): The Biotech Stock with Biggest Upside Potential

Insider Monkey
·
18 Jan

Roivant Sciences buys Immunovant Inc. shares and repurchases its own stock for $336.9 million each

GuruFocus.com
·
16 Jan